Compare Cassava Sciences Inc (FLNA) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Northrop Grumman Corporation — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Northrop Grumman Corporation trades at $526.11 (market cap $74.60B). The key difference: Northrop Grumman Corporation is far larger — about 1403.8× Cassava Sciences Inc's market cap, and Northrop Grumman Corporation pays a 1.79% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NOC | |
|---|---|---|
Market Cap | $53.14M | $74.60B |
Sector | Health | Industrials |
52-Week High | $4.64 | $768.02 |
52-Week Low | $1.09 | $496.02 |
Enterprise Value | -$33.43M | $88.82B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Northrop Grumman (NOC) trades at $528.67, down 2.43% amid broader defense sector weakness. The stock shows strong fundamentals with consistent earnings beats, a 10.8% net margin, and $95.6B backlog supporting revenue visibility. Technical indicators signal bearish momentum with price near support at $523, while RSI at 24 suggests potential oversold conditions. Recent news highlights expansion in missile defense and space systems amid increased NATO spending expectations.
NOC presents a compelling value opportunity with 57% analyst buy ratings and $655 price target implying 24% upside. Key catalysts include Q2 earnings beat potential and defense budget tailwinds, though political uncertainty and execution risks on large contracts remain concerns. The stock's 16.5 P/E ratio appears attractive relative to historical averages given its earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
